A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Clinical trial NCT04570423 · RECRUITING
Trial details
- NCT number
- NCT04570423
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-20
- Primary completion
- 2027-10-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.